Conference call regarding interim report Q3
3 november, 10:00
3 november, 10:00
Invitation to attend Surgical Science's conference call regarding presentation of the interim report January-September 2025. The presentation will be held in English.
Time: Thursday, November 13 at 11:00 a.m. CET
If you wish to participate via webcast, please use the link below. It will be possible to ask written questions via the webcast.
https://surgical-science-sweden.events.inderes.com/q3-report-2025/register
If you wish to participate via teleconference, please register via the link below. After registration, you will receive phone numbers and a conference ID to access the conference. It will be possible to ask oral questions via the telephone conference.
https://events.inderes.com/surgical-science-sweden/q3-report-2025/dial-in
Participants from Surgical Science are:
Tom Englund, CEO
Anna Ahlberg, CFO
A press release with Surgical Science's interim report for January-September 2025 will be published on November 13, 2025 at 07:30 a.m. CET.
Prior to the start of the conference call, presentation material will be available on the company's website, under Investors, Presentations.
Gothenburg, Sweden, November 3, 2025
Surgical Science Sweden AB (publ)
The press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
Surgical Science is a global leader in evidence-based medical simulation. The company’s virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room - enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge.
Surgical Science has approximately 330 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Seattle and Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB.
Attachments
3 november, 10:00
Invitation to attend Surgical Science's conference call regarding presentation of the interim report January-September 2025. The presentation will be held in English.
Time: Thursday, November 13 at 11:00 a.m. CET
If you wish to participate via webcast, please use the link below. It will be possible to ask written questions via the webcast.
https://surgical-science-sweden.events.inderes.com/q3-report-2025/register
If you wish to participate via teleconference, please register via the link below. After registration, you will receive phone numbers and a conference ID to access the conference. It will be possible to ask oral questions via the telephone conference.
https://events.inderes.com/surgical-science-sweden/q3-report-2025/dial-in
Participants from Surgical Science are:
Tom Englund, CEO
Anna Ahlberg, CFO
A press release with Surgical Science's interim report for January-September 2025 will be published on November 13, 2025 at 07:30 a.m. CET.
Prior to the start of the conference call, presentation material will be available on the company's website, under Investors, Presentations.
Gothenburg, Sweden, November 3, 2025
Surgical Science Sweden AB (publ)
The press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
Surgical Science is a global leader in evidence-based medical simulation. The company’s virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room - enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge.
Surgical Science has approximately 330 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Seattle and Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB.
Attachments
Förvaltarnas investeringar
Placerapodden
Analyser
Rapporter
SBB-affären
Förvaltarnas investeringar
Placerapodden
Analyser
Rapporter
SBB-affären
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 806,05